Ponatinib-d8

CAS: 1562993-37-6

Ref. TR-P688252

Produktinformation

• Name: Ponatinib-d8
• Synonyme: 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide-d8, AP 24534-d8
• Marke: TRC

Beschreibung

Applications Ponatinib-d8 is an isotope labelled compound of Ponatinib (P688250). Ponatinib is a tyrosine kinase inhibitors (TKI) and used to treat chronic myeloid leukemia (CML) (1,2,3). Ponatinib is also used in combination with other drugs, such as forskolin, to combat TKI resistance in patient with CML (3), targeted drug in small-cell lung cancer. It is a COVID19-related research product.
References Skora, L., et al.: ACS Med. Chem. Lett., PagesAhead of Print (2017); Uchibori, K., et al.: Nat. Commun., 8, 14768 (2017); Perrotti, D., et al.: Curr. Drug Targets, 18, 377 (2017); Santarpia, M., et al.: Trans. Lung Cancer Res., 5, 51 (2016); Halbach, S., et al.: Cell Commun. Signal., 14, 6 (2016)

Chemische Eigenschaften

• Molekulargewicht: 540.61
• Formel: C₂₉H₁₉D₈F₃N₆O
• Farbe/Form: Neat
• InChl: InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)/i12D2,13D2,14D2,15D2
• SMILES: [2H]C1([2H])N(C)C([2H])([2H])C([2H])([2H])N(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5cccnn45)c3)cc2C(F)(F)F)C1([2H])[2H]